[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624816":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":64,"collaborators":18,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":18,"enrollmentInfo":78,"targetDuration":18,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Thomas Jefferson University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiation axilla","EXPERIMENTAL","Participants will receive radiotherapy to one axilla affected by hidradenitis suppurativa.",[13],"Radiation: Radiated axilla",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-radiated Axilla","NO_INTERVENTION","The contralateral axilla will not receive radiotherapy and will continue on the current standard of care.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"RADIATION","Radiated axilla","Intervention: Radiation\n\nTotal dose: 45 Gy Fractionation: 3 Gy per fraction Schedule: Three fractions per week for approximately five weeks",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Gregory Alexander, MD","CONTACT","856-922-4800","gregory.alexander@jefferson.edu",{"name":32,"role":28,"phone":33,"phoneExt":18,"email":34},"Sherry Yang, MD","215-955-6680","Sherry.Yang@jefferson.edu",[36,52],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Jefferson Cherry Hill - Radiation Oncology","RECRUITING","Cherry Hill","New Jersey","08003","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-75.03073,39.93484,{"lat":48,"lon":47},[51],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"facility":5,"status":38,"city":53,"state":54,"zip":55,"country":42,"countryCode":43,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Philadelphia","Pennsylvania","19107",{"type":45,"coordinates":57},[58,59],-75.16362,39.95238,{"lat":59,"lon":58},[62],{"name":32,"role":28,"phone":33,"phoneExt":18,"email":63},"sherry.yang@jefferson.edu",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Gregory Alexander","Principal Investigator","100624816","radiotherapy-for-refractory-hidradenitis-suppurativa-100624816",false,"NCT07414550","Radiotherapy for Refractory Hidradenitis Suppurativa","Radiotherapy for Treatment of Recalcitrant Hidradenitis Suppurativa (RADIANT-SUPPoRT)","RADIANTSUPPoRT","Inclusion Criteria:\n\n* Male or female subjects between the age of 18 or older with moderate or severe HS (Hurley Stage II or III) with bilateral axillary disease of approximately equivalent disease severity will be included.\n* Patients on topical and\u002For systemic HS medications for at least 1 month will continue maintenance treatment throughout the study period as per standard of care.\n* Patients willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Pregnancy - Women of childbearing potential must use trial approved birth control and obtain a negative pregnancy test 7 days prior to radiotherapy CT simulation.\n* Severe autoimmune conditions including lupus, scleroderma and mixed connective tissue disease\n* Poorly controlled diabetes per physician discretion, HIV, Hepatitis B\u002FC.\n* Prior therapeutic radiotherapy.\n* Active malignancy.\n* Contraindication to radiotherapy as determined by treating radiation oncologist.\n* Patients who began new systemic treatment for their HS \\\u003C1 month prior to enrollment in trial\n* History of photosensitivity disorders or prior radiation sensitization syndromes\n* Any contraindication to radiotherapy as determined by the treating radiation oncologist.","ALL","18 Years",{"count":79,"type":80},10,"ESTIMATED","INTERVENTIONAL",[83],"NA","The goal of this clinical trial is to learn if high-dose radiotherapy can provide sustained disease relief in moderate to severe, treatment resistant Hidradenitis suppurativa patients; could include any of the following: any sex\u002Fgender, and those greater then 18 years old. The main question\\[s\\] it aims to answer are:\n\nOutcome measure 1: Will radiotherapy change the number of inflammatory nodules, abscesses, and draining sinus tracts in the treated axilla compared with the untreated axilla? Outcome measure 2: Will radiotherapy positively change a patient's quality of life, pain levels and symptom burden?\n\nParticipants will receive radiotherapy to one axilla affected by hidradenitis suppurativa. The contralateral axilla will not receive radiotherapy and will continue receiving the standard treatment regimen.\n\nParticipants will...\n\n* Attend a baseline dermatology skin evaluation, complete multiple surveys and an optional participation in a biopsy\n* Attend multiple radiation sessions over 5 weeks\n* Attend 2 follow up visits with dermatology for skin evaluation, complete follow up surveys, and an optional biopsy.",[86],"Hidradenitis Suppurativa (HS)",[88,89,90,91,92],"Hidradenitis suppurativa","HS","Radiotherapy","Radiation","Treatment resistant","2026-05-12",{"date":95,"type":96},"2026-05-15","ACTUAL",{"date":98,"type":80},"2026-05-01",{"date":100,"type":80},"2028-03-01",{"name":5,"class":6},2]